Resources
69 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 12/15/2023 (updated 3/28/2024)
The Opioid-Overdose Reduction Continuum of Care Approach is a guide for policymakers for implementing evidence-based strategies that address opioid overdose.
Posted 11/9/2023 (updated 3/28/2024)
The CDC has released updated HCV testing recommendations perinatally exposed infants and children.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 4/26/2023 (updated 3/27/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. This page contains the RCORP data collection resources for the Behavioral Health Care Support grantees.
Posted 4/26/2023 (updated 3/27/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. This page contains the RCORP data collection resources for the MAT Access grantees.
Posted 11/14/2022 (updated 3/27/2024)
In their new 2022 Clinical Practice Guideline, the Centers for Disease Control and Prevention (CDC) provides updated evidence and research on the risks and benefits of prescription opioids for acute, subacute, and chronic pain. These include dosing strategies, tapering and discontinuation, comparisons with nonopioid pain treatments, and risk mitigation strategies.
Posted 6/14/2022 (updated 3/27/2024)
In 2019, the National Institutes of Health (NIH) began supporting research on treatment for opioid use disorder in criminal justice settings. The Justice Community Opioid Innovation Network (JCOIN) studies the effectiveness of new medications and other interventions as part of the NIH HEAL Initiative – Helping to End Addiction Long-Term.
Posted 5/25/2022 (updated 3/27/2024)
CDC’s Division of Overdose Prevention has developed an interactive data visualization tool, the DOSE Dashboard, which displays current nonfatal overdose data. The nonfatal drug overdose data on this dashboard are from CDC’s Drug Overdose Surveillance and Epidemiology (DOSE) system, which captures electronic health record information in syndromic surveillance data systems. DOSE data can be used to compare monthly and annual trends in nonfatal drug overdose-related ED visits by drug type (i.e., all drugs, all opioids, heroin, and all stimulants), state, and sex and age group.
Posted 2/9/2022 (updated 3/26/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. These measures are pending OMB clearance and are subject to revision. This page contains the RCORP data collection resources for the Psychostimulant Support grantees only.
These documents will be updated as new guidance or data sources are identified. We encourage you to bookmark this page so you have the latest version available. Please send any measure-related questions to your HRSA Project Officer or email: rcorp-eval@jbsinternational.com.